Abstract

We report on a case of delayed hemolytic transfusion reaction (DHTR) occurred 7 days after an erythrocytapheresis or eritroexchange procedure (EEX) treated with rituximab and glucocorticoids in a 15-years old patient with sickle cell disease. EEX was performed despite a previous diagnosis of alloimmunization, in order to reduce hemoglobin S rate before a major surgery for avascular necrosis of the femoral head. A first dose of rituximab was administered before EEX. However, rituximab couldn’t prevent DHTR that occurred with acute hemolysis, hemoglobinuria and hyperbilirubinemia. A further dose of rituximab and three boli of methylprednisolone were given after the onset of the reaction. It is likely that the combined use of rituximab and steroids managed to gradually improve both patient’s general conditions and hemoglobin levels. Nor early or late side effects were registered in a 33-months follow-up period. This report suggests the potential effectiveness and safety of rituximab in combination with steroids in managing and mitigating the symptoms of delayed post-transfusional hemolytic reactions in alloimmunized patients affected by sickle cell disease with absolute need for erythrocytapheresis.

Highlights

  • Only Abstract e We report on a case of delayed hemolytic s transfusion reaction (DHTR) occurred 7 days u after an erythrocytapheresis or eritroexchange l procedure (EEX) treated with rituximab and ia glucocorticoids in a 15-years old patient with sickle cell disease

  • Rituximab might have a dual role in preventsurgery by reducing alloantibodies prohemoglobinuria, Hb: 7.2 g/dL as expected for surgical blood loss in the first day, Hb levels ly stably around 7 g/dL in the five days)

  • A dose of methylpreds nisolone was administered i.v. (25 mg/kg) and u a RBC transfusion was performed; the blood l unit was completely hemolyzed and ia hyperhemolysis was detected in the following c hours

Read more

Summary

Introduction

Only Abstract e We report on a case of delayed hemolytic s transfusion reaction (DHTR) occurred 7 days u after an erythrocytapheresis or eritroexchange l procedure (EEX) treated with rituximab and ia glucocorticoids in a 15-years old patient with sickle cell disease. A single dose of Rituximab (375 mg/m2) was scored in the immediate postoperative time used in several cases to treat ongoing hyperheadministered i.v. four days before EEX which and at 1 year follow-up.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.